NUVL

Nuvalent Inc

Add to Watchlist

Advanced Chart

74.110

+1.95(2.702%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

74.380

Open

72.000

VWAP

73.26

Vol

891.89K

Mkt Cap

5.34B

Low

71.130

Amount

65.34M

EV/EBITDA(TTM)

Total Shares

64.56M

4.34B

EV/OCF(TTM)

P/S(TTM)

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-1.254

-2.04%

-1.278

+21.71%

-1.210

+2.54%

Estimates Revision

The market is revising No Change the revenue expectations for Nuvalent, Inc. (NUVL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.65%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.4%

In Past 3 Month

Stock Price

Go Up

+0.65%

In Past 3 Month

9 Analyst Rating

56.34% Upside

Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 115.86 USD with a low forecast of 100.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

56.34% Upside

Current: 74.110

Low

100.00

Averages

115.86

High

140.00

56.34% Upside

Current: 74.110

Low

100.00

Averages

115.86

High

140.00

Goldman Sachs

Not Rated -> Buy

upgrade

$105

2025-06-30

Reason

Goldman Sachs

Price Target

$105

2025-06-30

upgrade

Not Rated -> Buy

Reason

Goldman Sachs assigned Nuvalent a Buy rating with a $105 price target, having previously initiated coverage at Not Rated. Upon the completion of zidesamtinib's pivotal Phase 2 ARROS-1 topline results in TKI pre-treated ROS1-positive non-small cell lung cancer patients, the firm moved on from its previous "Early-Stage Biotech" designation, telling investors that its Buy rating is supported by zidesamtinib's best-in-class efficacy and safety profile demonstrated in both of its Phase 1/2 studies.

Baird

Outperform

maintain

$105 -> $112

2025-06-25

Reason

Baird

Price Target

$105 -> $112

2025-06-25

maintain

Outperform

Reason

Baird raised the firm's price target on Nuvalent to $112 from $105 and keeps an Outperform rating on the shares. The firm updated its model following the release of pivotal data in Pretreated ROS1+NSCLC which confirmed its differentiated profile.

H.C. Wainwright

Swayampakula Ramakanth

Buy

maintain

$110 -> $130

2025-06-24

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$110 -> $130

2025-06-24

maintain

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Nuvalent to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluating zidesamtinib to treat ROS1-positive non-small cell lung cancer patients that have received prior (tyrosine kinase inhibitor therapy, the analyst tells investors in a research note. The firm says the overall response rate among all patients is 44%, and the patients showed good durability with duration of responses of 78% at 12 months and 62% at 18 months. H.C. Wainwright believes the data was "particularly encouraging" in the 55 patients who received only one prior line of TKI therapy, who achieved overall response rate of 51% and an 18- month duration of response of 93%.

Leerink

Outperform

maintain

$125 -> $140

2025-06-24

Reason

Leerink

Price Target

$125 -> $140

2025-06-24

maintain

Outperform

Reason

Leerink raised the firm's price target on Nuvalent to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent's zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by "unprecedented" durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of therapy.

UBS

David Dai

Hold

Strong Buy

Upgrades

$100

2025-03-14

Reason

UBS

David Dai

Price Target

$100

2025-03-14

Upgrades

Hold

Strong Buy

Reason

UBS analyst David Lai upgraded Nuvalent to Buy from Neutral with an unchanged price target of $100. The shares have been "beaten down" since September 2024, driven largely by the tough biotech tape and macro environment, the analyst tells investors in a research note. However, the firm believes the stock remains solid fundamentally with two "potentially best-in-class therapies" for non-small cell lung cancer with a combined $3.3B peak sales opportunity. UBS sees several near-term catalysts over the next 12 months for Nuvalent and a favorable risk/reward for the shares.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$110

2025-03-03

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$110

2025-03-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuvalent Inc (NUVL.O) is -15.30, compared to its 5-year average forward P/E of -16.60. For a more detailed relative valuation and DCF analysis to assess Nuvalent Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-16.60

Current PE

-15.30

Overvalued PE

-10.61

Undervalued PE

-22.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.01

Current EV/EBITDA

-12.38

Overvalued EV/EBITDA

-7.14

Undervalued EV/EBITDA

-18.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.34

Current PS

1292.84

Overvalued PS

120.60

Undervalued PS

-101.91